Answers are grounded in this paper and cite their sources.
Preclinical evaluation reveals prostate shrinkage without altering gonadal hormones in mice, suggesting therapeutic potential for benign prostatic hyperplasia.
Benzopyran selective estrogen receptor beta agonist-1 (SERBA-1) shows potent, selective binding and agonist function in estrogen receptor beta (ERbeta) in vitro assays. X-ray crystal structures of SERBA-1 in ERalpha and beta help explain observed beta-selectivity of this ligand. SERBA-1 in vivo demonstrates involution of the ventral prostate in CD-1 mice (ERbeta effect), while having no effect on gonadal hormone levels (ERalpha effect) at 10x the efficacious dose, consistent with in vitro properties of this molecule.
No takes yet. Share an insight, caveat, or question.
Norman et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: